CoChat

An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

Zheng, Bing, Yu, Shang-Fan, del Rosario, Geoffrey, Leong, Steven R., Lee, Genee Y., Vij, Rajesh, Chiu, Cecilia, Liang, Wei-Ching, Wu, Yan, Chalouni, Cecile, Sadowsky, Jack, Clark, Vanessa, Hendricks, Angela, Poon, Kirsten Achilles, Chu, Wayne, Pillow, Thomas, Schutten, Melissa M., Flygare, John, Polson, Andrew G. · 2019 · Clinical Cancer Research
Cited by 66

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Purpose: The treatment of acute myeloid leukemia (AML) has not significantly changed in 40 years. Cytarabine- and anthracycline-based chemotherapy induction regimens (7 + 3) remain the standard of care, and most patients have poor long-term survival. The reapproval of Mylotarg, an anti-CD33–calicheamicin antibody–drug conjugate (ADC), has demonstrated ADCs as a clinically validated option to enhance the effectiveness of induction therapy. We are interested in developing a next-generation ADC for AML to improve upon the initial success of Mylotarg. Experimental Design: The expression pattern of CLL-1 and its hematopoietic potential were investigated. A novel anti–CLL-1-ADC, with a highly potent pyrrolobenzodiazepine (PBD) dimer conjugated through a self-immolative disulfide linker, was developed. The efficacy and safety profiles of this ADC were evaluated in mouse xenograft models and in cynomolgus monkeys. Results: We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs. Our anti–CLL-1-ADC is highly effective at depleting tumor cells in AML xenograft models and lacks target independent toxicities at doses that depleted target monocytes and neutrophils in cynomolgus monkeys. Conclusions: Collectively, our data suggest that an anti–CLL-1-ADC has the potential to become an effective and safer treatment for AML in humans, by reducing and allowing for faster recovery from initial cytopenias than the current generation of ADCs for AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-0333

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 66

Metadata

Authors
Zheng, B., Yu, S.-F., del Rosario, G., Leong, S. R., Lee, G. Y., Vij, R., Chiu, C., Liang, W.-C., Wu, Y., Chalouni, C., Sadowsky, J., Clark, V., Hendricks, A., Poon, K. A., Chu, W., Pillow, T., Schutten, M. M., Flygare, J., & Polson, A. G.
Venue
Clinical Cancer Research
Published
2019-02-15
Volume
25
Issue
4
Pages
1358-1368
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2810896718
Cited by
66
References
5
FWCI
5.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0333
The paper
Zheng, B., Yu, S.-F., del Rosario, G., Leong, S. R., Lee, G. Y., Vij, R., Chiu, C., Liang, W.-C., Wu, Y., Chalouni, C., Sadowsky, J., Clark, V., Hendricks, A., Poon, K. A., Chu, W., Pillow, T., Schutten, M. M., Flygare, J., & Polson, A. G. (2019). An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0333

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.